Drug Profile
Research programme: antibody drug conjugate antineoplastics - Philochem/Servier
Alternative Names: SMDC + ADCLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Philochem; Servier
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in France
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in Switzerland
- 25 Aug 2017 Philochem and Servier agree to develop small molecule-based therapeutics for Undefined indication